HTX-011 effectively reduces postoperative pain intensity and opioid use in the elderly

HTX-011 (ZYNRELEF™) is an extended-release, dual-acting local anesthetic containing bupivacaine and meloxicam. In bunionectomy and herniorrhaphy studies, HTX-011 resulted in less postoperative pain and less opioid consumption versus bupivacaine HCl. Here we evaluate HTX-011 in patients aged ≥65 year...

Full description

Saved in:
Bibliographic Details
Published inPain management Vol. 12; no. 1; pp. 45 - 57
Main Authors Yip, Tina, Hu, Jia, Hawn, Pamela S, Yamamoto, Amy, Oderda, Gary
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.01.2022
Subjects
Aged
Analgesics, Opioid - therapeutic use
anesthetics
Anesthetics, Local
Bupivacaine
Double-Blind Method
geriatrics
Humans
medication safety
pain management
Pain, Postoperative - drug therapy
pharmacokinetics
pharmacokinetics
geriatrics
medication safety
pain management
anesthetics
Online AccessGet full text

Cover

More Information
Summary:HTX-011 (ZYNRELEF™) is an extended-release, dual-acting local anesthetic containing bupivacaine and meloxicam. In bunionectomy and herniorrhaphy studies, HTX-011 resulted in less postoperative pain and less opioid consumption versus bupivacaine HCl. Here we evaluate HTX-011 in patients aged ≥65 years. Patients received placebo, bupivacaine HCl or HTX-011 following surgery. End points included pain intensity, total opioid consumption, opioid-free patients and safety. HTX-011-treated patients reported lower postoperative pain through 72 h versus bupivacaine HCl and placebo. Elderly patients administered HTX-011 used fewer opioids versus bupivacaine HCl, and a greater proportion remained opioid-free through 72 h. HTX-011 was well tolerated with a safety profile similar to bupivacaine HCl and placebo. HTX-011 maintained effectiveness and was well tolerated in elderly patients. Clinical Trial registration numbers: and
ISSN:1758-1869
1758-1877
DOI:10.2217/pmt-2021-0043